Susquehanna International Group, LLP Aldeyra Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $68,585 - $135,880	21,500 Added 131.1%	37,900 $204,000
Q2 2024 Aug 15, 2024	BUY	$3.25 - $4.72 $10,075 - $14,632	3,100 Added 23.31%	16,400 $54,000
Q1 2024 May 07, 2024	SELL	$2.77 - $4.22 $80,607 - $122,802	-29,100 Reduced 68.63%	13,300 $43,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $80,556 - $332,088	-54,800 Reduced 56.38%	42,400 $148,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $331,162 - $442,272	-54,200 Reduced 35.8%	97,200 $649,000
Q2 2023 Aug 11, 2023	BUY	$7.11 - $11.89 $651,987 - $1.09 Million	91,700 Added 153.6%	151,400 $1.27 Million
Q1 2023 May 16, 2023	BUY	$5.77 - $9.93 $50,198 - $86,391	8,700 Added 17.06%	59,700 $592,000
Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $207,264 - $289,272	-40,800 Reduced 44.44%	51,000 $354,000
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $173,660 - $353,718	45,700 Added 99.13%	91,800 $490,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $295M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.